Loading clinical trials...
Loading clinical trials...
The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial
Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.
Age
20 - No limit years
Sex
ALL
Healthy Volunteers
No
Asan Medical Center
Seoul, Songpa-gu, South Korea
Pusan National University Hospital
Busan, South Korea
Chungbuk National University Hospital
Cheongju-si, South Korea
Kyungpook National University Chilgok Hospital
Daegu, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Eulji University Hospital
Daejeon, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
Hallym University Medical Center
Gyeonggi-do, South Korea
Hanyang University Guri Hospital
Gyeonggi-do, South Korea
Start Date
July 10, 2025
Primary Completion Date
March 31, 2028
Completion Date
March 31, 2028
Last Updated
December 30, 2025
2,340
ESTIMATED participants
Aspirin
DRUG
Clopidogrel
DRUG
Cilostazol
DRUG
Placebo
DRUG
Lead Sponsor
Asan Medical Center
Collaborators
NCT07140406
NCT07121088
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03186456